Background: Factor V (FV) G1691A and prothrombin G20210A mutations are the most common targets of genetic tests for thromboembolism. This study compared the ability of real-time PCR to detect FV G1691A and prothrombin G20210A (BioSewoom, Korea) with that of PCR-restriction fragment length polymorphism (RFLP) and direct sequencing, to evaluate diagnostic equivalency. Methods: Real-time PCR was compared with PCR-restriction fragment length polymorphism (RFLP) and direct sequencing using patients’ samples as well as heterozygous and homozygous World Health Organization (WHO) reference reagent DNA. The limit of detection (LoD) for real-time PCR was determined using WHO reference reagents. Results: All 141 and 156 patient samples were tested for the FV G1691A and prothrombin G20210A mutations, respectively; the results from all three methods (real-time PCR, PCRRFLP, and direct sequencing) consistently showed that the samples were wild type. Each of the three methods showed the same results in tests using heterozygous and homozygous DNA from the WHO reference reagents. The LoD of wild type and homozygous samples was 65.16 pg/mL for FV G1691A, and 61.3 pg/mL for prothrombin G20210A. The LoD of heterozygous samples was 1,650.0 pg/mL for FV G1691A and 1,640.0 pg/mL for prothrombin G20210A. Conclusions: The real-time PCR test kits for FV G1691A and prothrombin G20210A showed reliable equivalency with PCR-RFLP and direct sequencing, and could be useful tests to detect gene polymorphisms for thromboembolism. (J Lab Med Qual Assur 2015;37:37-43)

Keywords: Real-time polymerase chain reaction, Factor V G1691A, Prothrombin G20210A, Thrombophilic mutation , Factor V Leiden

1. Dahlback B. New molecular insights into the genetics of thrombophilia: resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost 1995;74:139-48.
   
2. Hooper WC, Dilley A, Ribeiro MJ, Benson J, Austin H, Silva V, et al. A racial difference in the prevalence of the Arg506-->Gln mutation. Thromb Res 1996;81:577-81.
   
3. Cordoba I, Pegenaute C, Gonzalez-Lopez TJ, Chillon C, Sarasquete ME, Martin-Herrero F, et al. Risk of placentamediated pregnancy complications or pregnancy-related VTE in VTE-asymptomatic families of probands with VTE and heterozygosity for factor V Leiden or G20210 prothrombin mutation. Eur J Haematol 2012;89:250-5.
   
4. Saemundsson Y, Sveinsdottir SV, Svantesson H, Svensson PJ. Homozygous factor V Leiden and double heterozygosity for factor V Leiden and prothrombin mutation. J Thromb Thrombolysis 2013;36:324-31.
   
5. Simone B, De Stefano V, Leoncini E, Z acho J, Martinelli I, Emmerich J, et al. Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a metaanalysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol 2013;28:621-47.
   
6. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
   
7. Kapur RK, Mills LA, Spitzer SG, Hultin MB. A prothrombin gene mutation is significantly associated with venous thrombosis. Arterioscler Thromb Vasc Biol 1997;17:2875-9.
   
8. Gerhardt A, Scharf RE, Beckmann MW, Struve S, Bender HG, Pillny M, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000;342:374-80.
   
9. Tempfer CB, Riener EK, Hefler LA, Huber JC, Muendlein A. DNA microarray-based analysis of single nucleotide polymorphisms may be useful for assessing the risks and benefits of hormone therapy. Fertil Steril 2004;82:132-7.
   
10. Maher C, Crowley D, Cullen C, Wall C, Royston D, Fanning S. Double fluorescent-amplification refractory mutation detection (dF-ARMS) of the factor V Leiden and prothrombin mutations. Thromb Haemost 1999;81:76-80.
    
11. Bozikova A, Gabrikova D, Sovicova A, Behulova R, Macekova S, Boronova I, et al. The frequency of factor V Leiden and prothrombin G20210A mutations in Slovak and Roma (Gypsy) ethnic group of Eastern Slovakia. J Thromb Thrombolysis 2012;34:406-9.
    
12. Bagheri M, Rad IA. A multiplex allele specific polymerase chain reaction (MAS-PCR) for the detection of factor V Leiden and prothrombin G20210A. Maedica (Buchar) 2011;6:3-9.
13. Agilent Technologies. Introduction to quantitative PCR:method and application guide. http://www.chem.agilent.com/Library/brochures/Brochure_Guide%20to%20QPCR_IN70200C.pdf (Accessed March, 2012).
14. De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica 2002;87:1095-108.
    
15. Lucotte G, Champenois T. Duplex PCR-RFLP for simultaneous detection of factor V Leiden and prothrombin G20210A. Mol Cell Probes 2003;17:267-9.
    
16. Emadi A, Crim MT, Brotman DJ, Necochea AJ, Samal L, Wilson LM, et al. Analytic validity of genetic tests to identify factor V Leiden and prothrombin G20210A. Am J Hematol 2010;85:264-70.
    
17. Laboratory Medicine Foundation. Clinical Laboratory Accreditation Program in Korea, Inspection check list, Molecular diagnostics. http://lmf.or.kr/sub/catalog.php? CatNo=65&OutLine=menu0outline. LaboratoryMedicine Foundation. (Accessed January, 2014).
18. Kim YW, Yoon KY, Park S, Shim YS, Cho HI, Park SS. Absence of factor V Leiden mutation in Koreans. Thromb Res 1997;86:181-2.
    
19. Song KS, Park YS, Kim HK, Choi JR. Absence of the prothrombin gene variant in Koreans. Thromb Haemost 1999;81:990.